Daily Endocrinology Research Analysis
Analyzed 29 papers and selected 3 impactful papers.
Summary
The most impactful studies span developmental neuroendocrinology, precision endocrine therapy, and long-acting hormone replacement. A single-nucleus multiomic study identified cell-type-specific transcriptional and chromatin changes caused by prenatal androgen exposure, while a prospective cohort showed that setmelanotide produces endocrine-axis effects beyond weight loss in Bardet-Biedl syndrome. A network meta-analysis further supports once-weekly growth hormone as an effective alternative to daily therapy in children with growth hormone deficiency.
Research Themes
- Developmental programming of neuroendocrine circuits in polycystic ovary syndrome
- Pleiotropic endocrine effects of melanocortin-4 receptor agonism
- Comparative efficacy and safety of long-acting growth hormone therapy
Selected Articles
1. A single-nucleus multiomic study of preoptic area cells in prepubertal control vs prenatally androgenized female mice.
Using single-nucleus RNA sequencing and assay for transposase-accessible chromatin sequencing, the investigators profiled 31 preoptic-area cell populations in a prenatal androgenization mouse model of polycystic ovary syndrome. Prenatal androgen exposure produced cell-type-specific transcriptional and chromatin-accessibility changes, including differentially accessible regions in gonadotropin-releasing hormone neurons and altered regulation of glial energy metabolism.
Impact: This study provides high-resolution, cell-type-specific evidence linking prenatal androgen excess to persistent neuroendocrine programming relevant to polycystic ovary syndrome. The integration of transcriptomic and chromatin data identifies candidate regulatory mechanisms that could guide future therapeutic research.
Clinical Implications: The findings strengthen the biological rationale for developmental and epigenetic contributions to polycystic ovary syndrome and may eventually support biomarker development or interventions directed at neuroendocrine circuit dysfunction. They do not yet justify changes to clinical management because the evidence is from a mouse model.
Key Findings
- Single-nucleus multiome sequencing identified 31 neuronal and non-neuronal populations in the preoptic area, including a manually curated cluster of 41 gonadotropin-releasing hormone neurons.
- Prenatal androgenization altered transcriptional programs across multiple cell types, with enrichment of protein synthesis and oxidative phosphorylation pathways and suppression of tumor necrosis factor/NF-kappa B signaling and steroid responsiveness.
- Approximately 30,600 chromatin-accessibility peaks were evaluated, identifying 15 significant differentially accessible regions, including two loci in gonadotropin-releasing hormone neurons and reduced Pgk1 promoter accessibility in several glial populations.
Methodological Strengths
- Single-nucleus transcriptomic and chromatin-accessibility measurements were integrated at cellular resolution.
- The analysis included broad profiling of 31 cell populations and manual refinement of the gonadotropin-releasing hormone neuron cluster.
Limitations
- The study used a prenatal androgenization mouse model, and the molecular findings may not fully translate to human polycystic ovary syndrome.
- The study was primarily observational at the molecular level and did not establish that the identified regulatory changes are causally responsible for the phenotype.
Future Directions: Future studies should validate the candidate chromatin regions and glial metabolic mechanisms with cell-type-specific perturbation, assess persistence across developmental stages, and compare these signatures with human hypothalamic or peripheral tissues from patients with polycystic ovary syndrome.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder with developmental origins. While the etiology is unclear, current postulates include epigenetic programming. Cell-type-specific epigenetic changes by which prenatal androgen excess programs the neuroendocrine axis have not been defined. Using single-nucleus (sn) multiome sequencing (snRNAseq + snATACseq) of the mouse preoptic area, we profiled transcriptional and chromatin accessibility landscapes across 31 cell populations on postnatal day 18-22 in a prenatal androgenization (PNA) mouse model that produces neuroendocrine phenotypes that resemble hyperandrogenemic PCOS.
2. Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.
In 58 genetically confirmed patients with Bardet-Biedl syndrome, prospective longitudinal treatment with the melanocortin-4 receptor agonist setmelanotide reduced BMI and glycated hemoglobin after 6 months. The treatment also increased gonadotropins, sex steroids, and insulin-like growth factor 1, while lowering thyroid-stimulating hormone without corresponding changes in peripheral thyroid hormones, indicating broad and partly weight-independent endocrine effects.
Impact: This is one of the first prospective clinical demonstrations that melanocortin-4 receptor agonism affects multiple endocrine axes beyond appetite and body weight in Bardet-Biedl syndrome. The findings may change how clinicians monitor reproductive, growth, and thyroid-related outcomes during treatment.
Clinical Implications: Clinicians using setmelanotide in Bardet-Biedl syndrome may need to monitor gonadal hormones, insulin-like growth factor 1, thyroid-stimulating hormone, glycemic status, and growth-related outcomes in addition to weight and appetite. The findings support individualized endocrine surveillance but do not establish treatment effects in randomized comparisons.
Key Findings
- Among 58 genetically confirmed patients, BMI and glycated hemoglobin decreased significantly after 6 months of setmelanotide therapy.
- Gonadotropins and testosterone or estradiol increased in an age-dependent manner, indicating activation of reproductive endocrine axes.
- Insulin-like growth factor 1 increased independently of weight change, while thyroid-stimulating hormone decreased without parallel changes in peripheral thyroid hormones; these effects persisted after the first 6 months.
Methodological Strengths
- Prospective longitudinal follow-up of genetically confirmed Bardet-Biedl syndrome patients receiving a clinically relevant therapy.
- Linear mixed-effects models adjusted for age, sex, and body mass index z-score to evaluate repeated endocrine measurements.
Limitations
- The study was a single-centre observational cohort without a randomized control group, so causal attribution to setmelanotide is limited.
- The sample size was modest and the rare-disease population may limit generalizability to other obesity or endocrine disorders.
Future Directions: Randomized or controlled comparative studies should determine whether the endocrine changes improve clinically meaningful outcomes, clarify mechanisms independent of weight loss, and establish monitoring and dose-adjustment strategies for children and adults with Bardet-Biedl syndrome.
BACKGROUND: Bardet-Biedl syndrome (BBS) is a rare ciliopathy characterized by early-onset obesity and multisystem endocrine dysfunction. The melanocortin-4 receptor (MC4R) agonist setmelanotide is approved for hyperphagia-related obesity in BBS, but its endocrine effects remain incompletely understood. METHODS: In this prospective single-centre observational cohort study, 58 genetically confirmed BBS patients initiating setmelanotide therapy were followed longitudinally. Linear mixed-effects models adjusted for age, sex, and BMI z-score were used to evaluate changes over time. FINDINGS: After 6 months, significant reductions in BMI and HbA1c were observed. Treatment was associated with increases in gonadotropins and testosterone and estradiol age-dependently. IGF-1 levels increased independently of weight change, while TSH decreased without corresponding changes in peripheral thyroid hormones. These effects were established within the first 6 months and remained stable thereafter.
3. Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials.
This network meta-analysis synthesized 18 randomized controlled trials involving 3,137 children with growth hormone deficiency. Weekly formulations generally provided comparable linear growth and discontinuation rates to daily somatropin, although treatment-specific differences were observed: YPEG-rhGH showed higher height velocity, lonapegsomatropin increased insulin-like growth factor 1 standard deviation scores, and somatrogon increased local injection-site reactions.
Impact: The study directly informs an important practical decision in pediatric endocrinology: selecting among weekly growth hormone formulations and daily therapy. Its formulation-specific efficacy and safety findings support individualized treatment selection and more appropriate interpretation of insulin-like growth factor 1 monitoring.
Clinical Implications: Once-weekly growth hormone can be considered a practical alternative to daily therapy when adherence or treatment burden is important. Clinicians should account for formulation-specific injection-site reactions and use the recommended post-dose sampling windows for insulin-like growth factor 1 interpretation, including 2-5 days for lonapegsomatropin and 96 hours for somatrogon.
Key Findings
- Eighteen randomized controlled trials involving 3,137 children were included in the network meta-analysis.
- Weekly YPEG-recombinant human growth hormone at 0.1 mg/kg/week produced significantly higher height velocity than daily somatropin in the primary random-effects model, while no significant differences across treatments were observed for height standard deviation score.
- Lonapegsomatropin 0.24 mg/kg/week increased insulin-like growth factor 1 standard deviation scores, whereas somatrogon significantly increased localized injection-site erythema and pain; overall discontinuation rates did not differ significantly.
Methodological Strengths
- The analysis synthesized direct and indirect evidence from 18 randomized controlled trials using a frequentist random-effects network meta-analysis.
- The review searched multiple major databases and included formulation-specific efficacy, biomarker, and safety outcomes; the protocol was registered on the Open Science Framework.
Limitations
- Network meta-analysis estimates depend on transitivity and comparability across trials, which may be limited by differences in populations, doses, follow-up, and outcome assessment.
- The abstract does not provide a complete assessment of heterogeneity, risk of bias, or the certainty of every indirect comparison.
Future Directions: Future head-to-head trials should compare long-acting formulations using standardized growth, insulin-like growth factor 1, adherence, patient-reported burden, and long-term safety outcomes. Studies should also evaluate cost-effectiveness and treatment preference across age groups and clinical subtypes.
INTRODUCTION: Current guidelines recognize daily recombinant human growth hormone (rhGH) as standard care and long-acting growth hormone (LAGH) as an alternative for paediatric growth hormone deficiency (CHD). In this network meta-analysis (NMA), we updated the evidence to evaluate comparative efficacy and safety of multiple dosing nodes of LAGH versus daily somatropin. METHODS: Major databases, including PubMed, Embase, Cochrane Central, Scopus, Web of Science, and http://ClinicalTrials.Gov, were searched through April 2026 for randomized controlled trials (RCTs)in children with CHD. Outcomes included height velocity (HV), height SDS, and adverse events. Direct and indirect evidence was synthesized using a frequentist random-effects NMA (OSF: https://doi.org/10.17605/osf.io/nugpe). RESULTS: Eighteen RCTs (n = 3137) were analysed. In the primary random-effects model for HV, weekly YPEG-rhGH 0.1 mg/kg/week showed a significantly higher velocity compared to daily Somatropin (SMD: 5.02), whereas Somatrogon 0.25/0.48/0.66 mg/kg/week and Somapacitan 0.04 mg/kg/week showed lower HV.